SciSparc: Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s

 

• Meets primary endpoints- SCI-110 administration was found to be safe at all tested doses

• SCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication to control agitation and 75% of patients experienced increased appetite

• SciSparc has previously shown positive results using SCI-110 in Tourette syndrome

https://finance.yahoo.com/news/scisparc-announced-positive-interim-results-134500709.html